Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma

Annals of Hematology

Volumn 91, Issue 3, 2012, Pages 419-426

  Zamagni, Elena ^a   Petrucci, Alessandro ^a   Tosi, Patrizia ^b   Tacchetti, Paola ^a   Perrone, Giulia ^a   Brioli, Annamaria ^a   Pantani, Lucia ^a   Zannetti, Beatrice ^a   Terragna, Carolina ^a   Baccarani, Michele ^a   Cavo, Michele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Infermi Hospital   (Italy)

Author keywords

First relapse; Multiple myeloma; Overall survival; Peripheral neuropathy; Progression free survival; Thalidomide

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BRADYCARDIA; CANCER CHEMOTHERAPY; CANCER RELAPSE; CONSTIPATION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HUMAN; INFECTION; INSOMNIA; LEUKOPENIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NEUTROPENIA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SALVAGE THERAPY; SIDE EFFECT; STEM CELL TRANSPLANTATION; VENOUS THROMBOEMBOLISM; WEIGHT GAIN;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MULTIPLE MYELOMA; RECURRENCE; SALVAGE THERAPY; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84857362265     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-011-1320-2     Document Type: Article

References (31)

1. RA Kyle SV Rajkumar 2004 Multiple myeloma N Engl J Med 351 1860 1873 15509819 10.1056/NEJMra041875 1:CAS:528:DC%2BD2cXptFChtLk%3D (Pubitemid 39426321)
2. M Attal JL Harousseau AM Stoppa, et al. 1996 A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome N Engl J Med 335 2 91 97 8649495 10.1056/NEJM199607113350204 1:STN:280:DyaK283ms1emuw%3D%3D (Pubitemid 26240110)
3. JA Child GJ Morgan FE Davies, et al. 2003 High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma N Engl J Med 348 19 1875 1883 12736280 10.1056/NEJMoa022340 1:CAS:528:DC%2BD3sXjsVChtLo%3D (Pubitemid 36532313)
4. SK Kumar V Rajkumar A Dispenzieri, et al. 2008 Improved survival in multiple myeloma and the impact of novel therapies Blood 111 5 2516 2520 17975015 10.1182/blood-2007-10-116129 1:CAS:528:DC%2BD1cXivFaktrk%3D
5. S Singhal J Metha R Desikan, et al. 1999 Antitumor activity of thalidomide in refractory multiple myeloma N Engl J Med 341 21 1565 1571 10564685 10.1056/NEJM199911183412102 1:CAS:528:DyaK1MXotVSgs78%3D
6. A Glasmacher C Hahn F Hoffmann, et al. 2006 A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma Br J Haematol 132 5 584 593 16445831 10.1111/j.1365-2141.2005.05914.x 1:CAS:528:DC%2BD28XislCqtb0%3D (Pubitemid 43381591)
7. M Von-Lilienfeld-Toal C Hahn-Ast K Furkert, et al. 2008 A systematic review of phase II trials of thalidomide-dexamethasone combination in patients with relapsed or refractory multiple myeloma Eur J Haematology 81 247 252 10.1111/j.1600-0609.2008.01121.x 1:CAS:528:DC%2BD1cXht1Kru7nM
8. A Palumbo T Facon P Sonneveld, et al. 2008 Thalidomide for treatment of multiple myeloma: 10 years later Blood 111 8 3968 3977 18245666 10.1182/blood-2007-10-117457 1:CAS:528:DC%2BD1cXkvFeju7c%3D
9. J Bladè D Samson D Reece, et al. 1998 Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation Br J Haematol 102 1115 1123 9753033 10.1046/j.1365-2141.1998.00930.x (Pubitemid 28435189)
10. M Cavo E Zamagni C Cellini, et al. 2002 Deep vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy Blood 100 6 2272 2273 12229885 10.1182/blood-2002-06-1674 1:CAS:528: DC%2BD38Xnt1yht74%3D (Pubitemid 35001274)
11. M Cavo F Di Raimondo E Zamagni, et al. 2009 Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma J Clin Oncol 27 30 5001 5007 19720903 10.1200/JCO.2009.22.7389 1:CAS:528:DC%2BD1MXhsVCrsrzI
12. A Corso P Zappasodi L Barbarano, et al. 2009 Long-term outcome in relapsed and refractory multiple myeloma treated with thalidomide. Balancing efficacy and side-effects Leuk Res 33 9 e145 e149 19375164 10.1016/j.leukres. 2009.03.015 1:CAS:528:DC%2BD1MXnvVakt7g%3D
13. P Tosi E Zamagni C Cellini, et al. 2002 Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma Haematologica 87 4 408 414 11940485 1:CAS:528:DC%2BD38XjvFSrsr0%3D (Pubitemid 34297548)
14. M Dimopoulos A Spencer M Attal, et al. 2007 Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma N Engl J Med 357 21 2123 2132 18032762 10.1056/NEJMoa070594 1:CAS:528:DC%2BD2sXhtlGis7nN (Pubitemid 350146107)
15. EA Stadtmauer D Weber R Niesvizky, et al. 2009 Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma Eur J Haematol 82 426 432 19302559 10.1111/j.1600-0609.2009.01257.x 1:CAS:528: DC%2BD1MXmtVyls78%3D
16. PG Richardson P Sonneveld MW Schuster, et al. 2005 Bortezomib or high-dose dexamethasone for relapsed multiple myeloma N Engl J Med 352 24 2487 2498 15958804 10.1056/NEJMoa043445 1:CAS:528:DC%2BD2MXltlaksLc%3D (Pubitemid 41007864)
17. PG Richardson P Sonneveld M Schuster, et al. 2007 Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial Blood 110 10 3557 3560 17690257 10.1182/blood-2006-08-036947 1:CAS:528:DC%2BD2sXhtlarur3K (Pubitemid 350159621)
18. PG Richardson P Sonneveld MW Schuster, et al. 2007 Safety and efficacy of bortezomib in high-risk and elederly patients with relapsed multiple myeloma Br J Haematol 137 429 435 17451408 10.1111/j.1365-2141.2007.06585.x 1:CAS:528:DC%2BD2sXotVOgsrk%3D (Pubitemid 46698286)
19. I Yakoub-Agha C Doyen C Hulin, et al. 2006 A multicenter prospective randomised study testing non inferiority of thalidomide 100mg/day as compared with 400mg/day in patients with refractory/relapsed multiple myeloma: results of the final analysis of the IFM-02 study J Clin Oncol 24 7520 10.1200/JCO.2006.08.0952 (Pubitemid 46631311)
20. F Van Rhee M Dhodapkar JD Shaughnessy, et al. 2008 First thalidomide clinical trial in multiple myeloma: a decade later Blood 112 4 1035 1038 18502827 10.1182/blood-2008-02-140954
21. P Tosi E Zamagni C Cellini, et al. 2005 Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma Eur J Haematol 74 3 212 216 15693790 10.1111/j.1600-0609.2004.00382.x 1:CAS:528:DC%2BD2MXis1Klsb0%3D (Pubitemid 40278490)
22. M Offidani L Corvatta M Marconi, et al. 2004 Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on dose-minimazing peripheral neuropathy Eur J Haematol 72 403 409 15128418 10.1111/j.1600-0609. 2004.00238.x 1:CAS:528:DC%2BD2cXlt1elurg%3D (Pubitemid 38703531)
23. R Plasmati F Pastorelli M Cavo, et al. 2007 Neuropathy in multiple myeloma treated with thalidomide: a prospective study in patients with newly diagnosed multiple myeloma Neurology 69 573 581 17679676 10.1212/01.wnl. 0000267271.18475.fe 1:CAS:528:DC%2BD2sXotlKjsb0%3D (Pubitemid 47357264)
24. M Hussein V Bolejack JA Zonder, et al. 2009 Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide plus prednisone maintenance for untreated multiple myeloma: a southwest Oncology Group Trial (SO204) J Clin Oncol 27 21 3510 3517 19546405 10.1200/JCO.2008.19.9240 1:CAS:528:DC%2BD1MXhtVSqtLjP
25. M Cavo L Pantani P Tacchetti, et al. 2009 Thalidomide maintenance in multiple myeloma: certainties and controversies J Clin Oncol 27 32 e186 e187 19770366 10.1200/JCO.2009.24.0150
26. JE Chang MB Juckett NS Callander, et al. 2008 Thalidomide maintenance following high-dose melphalan with autologous stem cell support in myeloma Clin Lymphoma Myeloma 8 3 153 158 18650178 10.3816/CLM.2008.n.018 1:CAS:528:DC%2BD1cXoslOqtrk%3D
27. A Spencer HM Prince AW Roberts, et al. 2009 Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure J Clin Oncol 27 11 1788 1793 19273705 10.1200/JCO.2008.18.8573 1:CAS:528:DC%2BD1MXltlSisrY%3D
28. JF San Miguel MA Dimopoulos EA Stadtmauer, et al. 2010 Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone Clin Lymphoma Myeloma Leuk 120 1 6 10.3816/CLML.2010.n.120
29. M Von Lilienfeld-Toal C Hahn-Ast F Bertolini, et al. 2007 Longer duration of thalidomide monotherapy results in improved outcome in relapsed/refractory multiple myeloma Blood 110 800a
30. GJ Morgan GH Jackson F Davies, et al. 2008 Maintenance thalidomide may improve progression free survival but not overall survival; results from the myeloma XI maintenance randomisation Blood 112 656a
31. GJ Morgan FE Davies WM Gregory, et al. 2010 Thalidomide maintenance significantly improves progression free survival (PFS) and overall survival (OS) of myeloma patients when effective relapse treatments are used: MRC myeloma IX results Blood 116 623a